Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
165,974,436
-
Total 13F shares
-
40,971,724
-
Share change
-
+40,254,597
-
Total reported value
-
$120,062,000
-
Put/Call ratio
-
34%
-
Price per share
-
$2.93
-
Number of holders
-
85
-
Value change
-
+$117,961,261
-
Number of buys
-
84
Institutional Holders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) as of Q4 2021
As of 31 Dec 2021,
Xeris Biopharma Holdings, Inc. - Common Stock (XERS) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,971,724 shares.
The largest 10 holders included
CAXTON CORP, Stonepine Capital Management, LLC, VANGUARD GROUP INC, NEA Management Company, LLC, LAZARD ASSET MANAGEMENT LLC, Invesco Ltd., BlackRock Inc., Man Group plc, MORGAN STANLEY, and Redmile Group, LLC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.